$3.59B in CY2024 Part D spend5.6M claims · 1.6M beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Mirabegron used for?
Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and....
Is there a generic for Mirabegron?
Yes. 13 ANDAs filed at FDA, 6 generic manufacturers currently shipping.
How much does my plan pay for Mirabegron?
Across 329 Part D plans, Mirabegron averages $10.59/unit (NADAC). Lowest available: $2.21/unit. Highest in distribution: $14.70/unit.
Is Mirabegron on the FDA shortage list?
No. Mirabegron is not currently on the FDA Drug Shortage Database.
9 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.